Data Insights

Psilocybin by Compass Pathways for Treatment Resistant Depression: Likelihood of Approval

Psilocybin is under clinical development by Compass Pathways and currently in Phase III for Treatment Resistant Depression. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Treatment Resistant Depression

Data Insights

Psilocybin by Ceruvia Lifesciences for Smoking Cessation: Likelihood of Approval

Psilocybin is under clinical development by Ceruvia Lifesciences and currently in Phase II for Smoking Cessation. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Smoking Cessation

Data Insights

Psilocybin by Compass Pathways for Anorexia Nervosa: Likelihood of Approval

Psilocybin is under clinical development by Compass Pathways and currently in Phase II for Anorexia Nervosa. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Anorexia Nervosa

Data Insights

Psilocybin by Nova Mentis BioTech for Fragile X Syndrome: Likelihood of Approval

Psilocybin is under clinical development by Nova Mentis BioTech and currently in Phase II for Fragile X Syndrome. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Fragile X Syndrome

Data Insights

Psilocybin by Nova Mentis BioTech for Autism Spectrum Disorder (ASD): Likelihood of Approval

Psilocybin is under clinical development by Nova Mentis BioTech and currently in Phase II for Autism Spectrum Disorder (ASD). According...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Autism Spectrum Disorder (ASD)

Data Insights

Psilocybin by Filament Health for Treatment Resistant Depression: Likelihood of Approval

Psilocybin is under clinical development by Filament Health and currently in Phase II for Treatment Resistant Depression. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Treatment Resistant Depression

Data Insights

Psilocybin by Compass Pathways for Treatment Resistant Depression: Likelihood of Approval

Psilocybin is under clinical development by Compass Pathways and currently in Phase III for Treatment Resistant Depression. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Treatment Resistant Depression

Data Insights

Psilocybin by Compass Pathways for Body Dysmorphic Disorder: Likelihood of Approval

Psilocybin is under clinical development by Compass Pathways and currently in Phase II for Body Dysmorphic Disorder. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Body Dysmorphic Disorder

Data Insights

Psilocybin by Compass Pathways for Body Dysmorphic Disorder: Likelihood of Approval

Psilocybin is under clinical development by Compass Pathways and currently in Phase II for Body Dysmorphic Disorder. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Body Dysmorphic Disorder

Data Insights

Psilocybin by Ceruvia Lifesciences for Cluster Headache Syndrome (Cluster Headache): Likelihood of Approval

Psilocybin is under clinical development by Ceruvia Lifesciences and currently in Phase I for Cluster Headache Syndrome (Cluster Headache). According...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Cluster Headache Syndrome (Cluster Headache)

Data Insights

Risk adjusted net present value: What is the current valuation of Compass Pathways's Psilocybin?

Psilocybin is a small molecule commercialized by Compass Pathways, with a leading Phase III program in Treatment Resistant Depression. According...

Net Present Value Model: Compass Pathways Plc's Psilocybin

Data Insights

Psilocybin by Compass Pathways for Obsessive-Compulsive Disorder: Likelihood of Approval

Psilocybin is under clinical development by Compass Pathways and currently in Phase I for Obsessive-Compulsive Disorder. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Obsessive-Compulsive Disorder

Data Insights

Psilocybin by MycoMedica Life Sciences PBC for Obsessive-Compulsive Disorder: Likelihood of Approval

Psilocybin is under clinical development by MycoMedica Life Sciences PBC and currently in Phase I for Obsessive-Compulsive Disorder. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Obsessive-Compulsive Disorder

Data Insights

Psilocybin by MycoMedica Life Sciences PBC for Opium (Opioid) Addiction: Likelihood of Approval

Psilocybin is under clinical development by MycoMedica Life Sciences PBC and currently in Phase I for Opium (Opioid) Addiction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Opium (Opioid) Addiction

Data Insights

Psilocybin by MycoMedica Life Sciences PBC for Premenstrual Dysphoric Disorder (PMDD): Likelihood of Approval

Psilocybin is under clinical development by MycoMedica Life Sciences PBC and currently in Phase I for Premenstrual Dysphoric Disorder (PMDD)....

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Premenstrual Dysphoric Disorder (PMDD)

Data Insights

Psilocybin by Compass Pathways for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval

Psilocybin is under clinical development by Compass Pathways and currently in Phase II for Post-Traumatic Stress Disorder (PTSD). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Post-Traumatic Stress Disorder (PTSD)

Data Insights

Psilocybin by Tryptamine Therapeutics for Irritable Bowel Syndrome: Likelihood of Approval

Psilocybin is under clinical development by Tryptamine Therapeutics and currently in Phase II for Irritable Bowel Syndrome. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Irritable Bowel Syndrome

Data Insights

Psilocybin by Tryptamine Therapeutics for Fibromyalgia (Fibromyalgia Syndrome): Likelihood of Approval

Psilocybin is under clinical development by Tryptamine Therapeutics and currently in Phase II for Fibromyalgia (Fibromyalgia Syndrome). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Fibromyalgia (Fibromyalgia Syndrome)